Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) by variation of ring substituents
Gust, Ronald, Karl, Johann, Faderl, Michael and Schönenberger, Helmut (1995) Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) by variation of ring substituents. Archiv der Pharmazie 328 (5), pp. 457-463.Date of publication of this fulltext: 10 Nov 2010 12:01
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Archiv der Pharmazie | ||||
| Publisher: | Wiley | ||||
|---|---|---|---|---|---|
| Volume: | 328 | ||||
| Number of Issue or Book Chapter: | 5 | ||||
| Page Range: | pp. 457-463 | ||||
| Date | 1995 | ||||
| Additional Information (public) | CAN 123:74226 1-3 Pharmacology 105855-87-6; 105856-21-1; 105856-22-2; 105856-23-3; 105928-14-1; 105990-36-1; 165289-81-6 Role: BAC (Biological activity or effector, except adverse), BPR (Biological process), BSU (Biological study, unclassified), PRP (Properties), THU (Therapeutic use), BIOL (Biological study), PROC (Process), USES (Uses) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents); 10025-99-7; 111112-21-1 Role: RCT (Reactant), RACT (Reactant or reagent) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) | ||||
| Institutions | Chemistry and Pharmacy > Institute of Pharmacy > Alumni or Retired Professors > Prof. Schönenberger | ||||
| Identification Number |
| ||||
| Keywords | Conformation and Conformers (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Estrogen receptors Role: BPR (Biological process), BSU (Biological study, unclassified), BIOL (Biological study), PROC (Process) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) Estrogens Role: BSU (Biological study, unclassified), BIOL (Biological study) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Receptors Role: BPR (Biological process), BSU (Biological study, unclassified), BIOL (Biological study), PROC (Process) (estrogen, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) Molecular structure-biological activity relationship (estrogenic, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Neoplasm inhibitors (mammary gland, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Mammary gland (neoplasm, inhibitors, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Molecular structure-biological activity relationship (neoplasm-inhibiting, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) phenylethyleneamine platinum complex mammary antitumor estrogenic mammary cancer inhibitor phenylethyleneamine platinum complex | ||||
| Dewey Decimal Classification | 500 Science > 540 Chemistry & allied sciences | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 17706 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric